MedTrace Logo

A Study to Evaluate the Safety, Tolerability and Immunogenicity of a Universal Influenza A Vaccine

NCT01265914 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2012-03-26

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety, tolerability and immunogenicity of ascending doses of a novel, universal flu vaccine, in healthy volunteers.

Conditions

Interventions

BIOLOGICAL

FP-01.1

Ascending doses of FP-01.1 will be administered

BIOLOGICAL

placebo

Sponsors & Collaborators

  • Hammersmith Medicines Research

    collaborator OTHER

  • Immune Targeting Systems Ltd

    lead INDUSTRY

Principal Investigators

  • Steve Warrington, MD · Hammersmith Medicines Research

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2011-03-31
Completion
2011-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01265914 on ClinicalTrials.gov